-
Amylin Pharmaceuticals Files Suit Against Eli Lilly
Monday, May 16, 2011 - 7:11am | 119Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) today announced that it has filed a lawsuit against Eli Lilly and Company (NYSE: LLY) in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic...
-
Wedbush Raises PT On SIGA Technologies To $23
Monday, May 16, 2011 - 6:43am | 27Wedbush Securities has raised the price target on SIGA Technologies (NASDAQ: SIGA) from $17 to $23 and maintains its Outperform rating.
-
Earnings Scheduled For May 16 (VOXX, JCP, ALN, LOW, STV, WINN, SORL, GLPW, CTRP, URBN, JST, ZOOM, DL, MNOV, DRJ, JADE, FMD, CTC, GLGL, CHGS, GOK, GSL)
Monday, May 16, 2011 - 12:48am | 581Audiovox Corporation (NASDAQ: VOXX) is estimated to post its FQ4 earnings at $0.02 per share. J.C. Penney Company Inc (NYSE: JCP) is projected to report its Q1 EPS at $0.25 on revenue of $3.95 billion. American Lorain Corporation (AMEX: ALN) is expected to report its Q1 EPS at $0.08 on revenue...
-
17 Breakout Momentum Stocks
Sunday, May 15, 2011 - 10:48pm | 3381Click here for a FREE Trading Course Follow me on Twitter! Each week I publish stocks to watch for the upcoming week as potential momentum trades. The stocks below all have a 50k minimum average daily share volume and traded at a 52-week high on strong volume, with a minimum of two times relative...
-
Most Popular Stocks Right Now on 5/14/11- RMBS, HCEI, LPHI, DDS, BOCL, FXE, CYCC, EPB, ATEA
Saturday, May 14, 2011 - 12:32pm | 1052Rambus Inc. (RMBS), a premier technology licensing company, is trading at a price of $15.83, a dramatic change of -17.85%. Currently, the company has a Market capitalization (total value of a company in the stock market) of approximately 1.70B HEALTHY COFFEE INTL (HCEI) is trading at a price of $...
-
Biotech/Pharma Stock News Alert: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)
Friday, May 13, 2011 - 1:09pm | 1426Point Roberts, WA - May 13 2011 - Investorideas.com. a leader in sector stock research including biotech and pharma stocks issues a sector snapshot of three companies, Aethlon Medical, Inc. (OTCBB: AEMD), Vertex Pharmaceuticals Inc. (VRTX), Merck & Company, Inc. (NYSE: MRK) and their...
-
CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in Poland
Friday, May 13, 2011 - 9:01am | 123CEL-SCI Corporation (NYSE: CVM) announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in...
-
Biotech/Pharma Stocks: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)
Friday, May 13, 2011 - 9:00am | 53Point Roberts, WA - May 13 2011 - Investorideas.com. a leader in sector stock research including biotech and pharma stocks issues a sector snapshot of three companies, Aethlon Medical, Inc. (OTCBB: AEMD), Vertex Pharmaceuticals Inc. (VRTX), Merck & Company, Inc. (NYSE: MRK) and their...
-
Biotech/Pharma Stocks: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)
Friday, May 13, 2011 - 9:00am | 53Point Roberts, WA - May 13 2011 - Investorideas.com. a leader in sector stock research including biotech and pharma stocks issues a sector snapshot of three companies, Aethlon Medical, Inc. (OTCBB: AEMD), Vertex Pharmaceuticals Inc. (VRTX), Merck & Company, Inc. (NYSE: MRK) and their...
-
Oppenheimer Comments On 3SBio's 1Q Revenue
Friday, May 13, 2011 - 8:19am | 843SBio Inc.'s (NASDAQ: SSRX) 1Q revenue of $18.1M beat consensus estimate of $17.6M, Oppenheimer reports. “EPS of $0.15 missed consensus and our estimate by $0.02,” Oppenheimer writes. “SSRX maintained FY2011 revenue growth rate guidance of 20-30%. Pricing remains stable and we expect the lift of...
-
J.P. Morgan Maintains Overweight Rating on Lexicon Pharmaceuticals
Friday, May 13, 2011 - 8:06am | 132J.P. Morgan is maintaining its OW rating on Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX). “We are maintaining our OW rating on LXRX following today's R&D Day in NY, at which the company provided several incremental updates across its development pipeline,” J.P. Morgan writes. “All programs are...
-
J.P. Morgan Raises Target On Amgen To $70
Friday, May 13, 2011 - 7:44am | 265According to J.P. Morgan, Amgen (NASDAQ: AMGN) target is raised to $70. J.P. Morgan said that Amgen's fundamentals are balanced by two primary issues: upside potential from Prolia/Xgeva (dmab) and downside risk from the anemia (ESA) franchise. “These two issues drive sentiment on AMGN shares and...
-
JP Morgan Raises PT On Amgen To $70
Friday, May 13, 2011 - 6:13am | 26JP Morgan has raised the price target on Amgen (NASDAQ: AMGN) from $65 to $70 and maintains its Overweight rating.
-
Earnings Scheduled For May 13 (A, SVA, CADC, TRIT, ERF, VALV, GNET, TRBR, SIHI)
Friday, May 13, 2011 - 12:59am | 242Agilent Technologies Inc (NYSE: A) is projected to report its FQ2 EPS at $0.65 on revenue of $1.60 billion. Sinovac Biotech Ltd (NASDAQ: SVA) is expected to post its Q1 earnings at $0.01 per share on revenue of $4.52 million. China Advanced Construction Materials Group Inc (NASDAQ: CADC) is...
-
Vical Incorporated Up 18% On Heavy Volume (VICL)
Thursday, May 12, 2011 - 3:25pm | 91Vical Incorporated (NASDAQ: VICL) shares are soaring today on nearly seven times the average daily volume. At last check, shares of Vical Incorporated were trading at $4.68, a gain of 73 cents or 18.5%. The move comes on 2 million shares, which is well above the average daily volume of 300,00...